- 10:43 AM Astec Lifesciences may test Rs 150-200: Tulsian
- 10:37 AM Expect post bonus correction in RIL: Tulsian
- 10:33 AM CBI pegs Satyam scam losses at Rs 14000 cr
- 10:30 AM Suzlon Energy's Australian arm bags 42 MW order; s...
- 10:29 AM RIL ex-bonus, F&O expiry eyed: Udayan
- 10:24 AM Buy Nalco, says Sukhani
- 10:18 AM Mkts to remain strong; bet on midcaps: Ramesh Dama...
- 10:17 AM Keep Rs 340 stoploss in HPCL: Sukhani
- 10:12 AM Buy GSPL, says Sudarshan Sukhani
- 10:12 AM High tech storage to preserve British Library book...



Dr Reddy has crossed a billion dollars in revenues, and that makes it the second Indian company after Ranbaxy to scale the magic figure, reports CNBC-TV18.
For drug maker Dr Reddy's, year 2006 has been the most significant so far. Dr Reddy's has already achieved a billion dollars in global sales and looks set to better this figure by end of the financial year.
The major contributor to Dr Reddy's revenues has been the pact with US drug maker Merck to sell authorised versions of blockbuster heart drug Zocor and Proscar prescribed for prostate disease.
The pact for the two drugs, which is effective for the six months between June and December, contributed almost 40% or Rs 780 crore of the second quarter revenues of Rs 1,944 crore for Dr Reddy's.
Interestingly, for the whole of last year, Dr Reddy's sales stood at Rs 2,355 crore. Besides, during the year Dr Reddy's acquired Betapharm in Germany for USD 570 million dollars.
Betapharm sales, of about USD 140 million, is also expected to add up to Dr Reddy's sales. Dr Reddy's also banked heavily on marketing Fexofenadine or the generic version of the anti-histamine drug Allegra, analysts say.
In the next two weeks, the US FDA approval for Zofran or anti-emetic drug Ondansetron, may provide the next revenue trigger for Dr Reddy's.
However, analysts say it may get tough for Dr Reddy's to maintain the growth momentum for the next year, unless some big research deals are struck or patent challenge cases are settled out of court with US corporations.
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Expert sector picks to power your portfolio ahead

- Mitesh Thacker's top 5 picks for trade today

- Will ITC dream run continue beyond FY10?

- Moody's maintains negative view on India's credit condition

- Sudarshan Sukhani's top five picks for today's trade
- Ganeshaspeaks: Market prediction for Nov 25
- CBI catches top CLB official accepting Rs 6 lakh as bribe

- Bollywood actress Shilpa Shetty marries Raj Kundra
- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line










